NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $17.20
Forecasted Upside: -10.28 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
2 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$19.17 As of 06/18/2021 01:00 AM ET

▼ -0.38 (-1.94%)

1 month | 3 months | 12 months

Get New Vanda Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VNDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VNDA

^$17.20

▼ -10.28% Downside Potential

This price target is based on 4 analysts offering 12 month price targets for Vanda Pharmaceuticals in the last 3 months. The average price target is $17.20, with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a -10.28% upside from the last price of $19.17.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Vanda Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

12/26/2019

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

3/25/2020

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

6/23/2020

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

9/21/2020

0 strong buy ratings
2 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

12/20/2020

0 strong buy ratings
1 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/20/2021

0 strong buy ratings
2 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/19/2021

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/12/2021	Bank of America	Initiated Coverage	Buy	$22.00	Low
2/11/2021	Citigroup	Boost Price Target		$14.00 ➝ $18.00	Low
1/14/2021	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Medium
1/14/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$14.00	Medium
12/3/2020	Jefferies Financial Group	Boost Price Target		$16.00 ➝ $18.00	High
10/29/2020	Smith Barney Citigroup	Upgrade	Neutral ➝ Buy		High
10/29/2020	UBS Group	Upgrade	Neutral ➝ Buy	$14.00	High
10/29/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Neutral ➝ Buy	$14.00	High
6/9/2020	Citigroup	Downgrade	Buy ➝ Neutral	$14.00	High
5/6/2020	Stifel Nicolaus	Reiterated Rating	Hold	$13.00	High
3/16/2020	Oppenheimer	Downgrade	Market Perform ➝ Underperform		High
3/15/2020	Stifel Nicolaus	Reiterated Rating	Hold	$13.00	High
3/12/2020	Citigroup	Upgrade	Neutral ➝ Buy	$14.00	High
2/27/2020	Oppenheimer	Lower Price Target		$18.00 ➝ $12.00	High
2/26/2020	Stifel Nicolaus	Lower Price Target	Hold	$17.00 ➝ $13.00	High
2/26/2020	JMP Securities	Reiterated Rating	Outperform	$52.00 ➝ $25.00	High
2/2/2020	Stifel Nicolaus	Reiterated Rating	Hold		High
11/7/2019	Citigroup	Downgrade	Buy ➝ Neutral	$19.00	Low
11/7/2019	Stifel Nicolaus	Reiterated Rating	Hold	$17.00	High
8/1/2019	Citigroup	Upgrade	Neutral ➝ Buy	$19.00	High
7/31/2019	Stifel Nicolaus	Reiterated Rating	Hold	$17.00	High
7/24/2019	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$26.00 ➝ $17.00	High
5/5/2019	Oppenheimer	Set Price Target	Hold	$18.00	High
5/2/2019	Citigroup	Downgrade	Buy ➝ Neutral		High
2/14/2019	Oppenheimer	Lower Price Target		$29.00 ➝ $21.00	High
2/14/2019	Stifel Nicolaus	Reiterated Rating	Buy	$40.00	Low
2/14/2019	Cantor Fitzgerald	Reiterated Rating	Hold ➝ Reduce	$26.00	High
2/6/2019	Stifel Nicolaus	Reiterated Rating	Buy		High
2/6/2019	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$38.00 ➝ $30.00	High
12/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$43.00	Medium
12/11/2018	CIBC	Reiterated Rating	Outperform ➝ Market Perform		Low
12/11/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $44.00	Low
12/11/2018	Oppenheimer	Downgrade	Outperform ➝ Hold	$29.00	Medium
12/11/2018	UBS Group	Downgrade	Outperform ➝ Market Perform		Medium
12/10/2018	Cantor Fitzgerald	Set Price Target	Buy	$43.00	Low
12/7/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$31.00 ➝ $47.00	Medium
12/6/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Market Outperform	$36.00 ➝ $52.00	Low
12/4/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $40.00	High
12/4/2018	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$43.00	High
12/3/2018	Oppenheimer	Reiterated Rating	Buy		High
12/3/2018	Stifel Nicolaus	Set Price Target	Buy	$36.00	High
11/15/2018	Jefferies Financial Group	Set Price Target	Buy	$30.00	Low
11/8/2018	Stifel Nicolaus	Set Price Target	Buy	$31.00	Low
11/8/2018	Jefferies Financial Group	Initiated Coverage	Buy	$26.00	High
11/8/2018	Oppenheimer	Set Price Target	Buy	$29.00	N/A
10/31/2018	Stifel Nicolaus	Reiterated Rating	Buy		Low
10/16/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $31.00	High
10/3/2018	Oppenheimer	Set Price Target	Buy	$29.00	Low
10/3/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$26.00	Low
9/21/2018	CIBC	Reiterated Rating	Outperform ➝ Outperform		Low
9/20/2018	Oppenheimer	Initiated Coverage	Outperform ➝ Buy	$27.00 ➝ $29.00	Low
9/13/2018	Stifel Nicolaus	Initiated Coverage	Buy	$30.00	High
8/22/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$26.00	High
8/2/2018	Oppenheimer	Set Price Target	Buy	$27.00	Medium
8/2/2018	Seaport Global Securities	Reiterated Rating	Buy	$26.00	Medium
5/23/2018	Citigroup	Initiated Coverage	Buy	$26.00	Medium
5/3/2018	Oppenheimer	Set Price Target	Buy	$27.00	High
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Low
3/5/2018	Oppenheimer	Set Price Target	Buy	$27.00	Low
2/28/2018	Seaport Global Securities	Reiterated Rating	Buy	$21.00	Low
2/15/2018	Oppenheimer	Set Price Target	Buy	$27.00	High
2/13/2018	Jefferies Financial Group	Reiterated Rating	Buy	$20.00	Low
1/19/2018	Seaport Global Securities	Initiated Coverage	Buy ➝ Buy	$20.00	Medium
1/8/2018	Oppenheimer	Reiterated Rating	Buy		High
11/12/2017	Oppenheimer	Reiterated Rating	Buy	$25.00	N/A
10/29/2017	Oppenheimer	Set Price Target	Buy	$21.00 ➝ $26.00	N/A
10/19/2017	Piper Jaffray Companies	Set Price Target	Buy	$26.00	N/A
9/14/2017	Oppenheimer	Reiterated Rating	Buy	$21.00	High
9/14/2017	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Overweight	$23.00 ➝ $26.00	High
8/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$21.00	High
8/3/2017	Piper Jaffray Companies	Set Price Target	Buy	$23.00	High
8/3/2017	HC Wainwright	Set Price Target	Buy	$18.00	High
8/3/2017	Oppenheimer	Set Price Target	Buy	$21.00	High
6/27/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$23.00	Low
5/26/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$18.00	Low
5/25/2017	Jefferies Financial Group	Reiterated Rating	Buy	$21.00	Medium
4/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$21.00	Low
4/12/2017	CIBC	Reiterated Rating	Outperform ➝ Outperform	$21.00	Low
4/12/2017	Oppenheimer	Initiated Coverage	Outperform	$21.00	Low
2/2/2017	Jefferies Financial Group	Set Price Target	Buy	$21.00	N/A
1/8/2017	Jefferies Financial Group	Reiterated Rating	Buy	$23.00	N/A
11/9/2016	Aegis	Initiated Coverage	Buy	$24.00	N/A
10/24/2016	Piper Jaffray Companies	Set Price Target	Buy	$19.00	N/A
10/10/2016	Brean Capital	Set Price Target	Buy	$24.00	N/A
10/6/2016	Jefferies Financial Group	Initiated Coverage	Buy	$15.00 ➝ $23.00	N/A
10/1/2016	Piper Jaffray Companies	Set Price Target	Buy	$19.00	N/A
8/29/2016	Brean Capital	Reiterated Rating	Buy	$20.00 ➝ $24.00	N/A
8/26/2016	JMP Securities	Boost Price Target	Market Outperform	$18.00 ➝ $22.00	N/A
8/18/2016	Piper Jaffray Companies	Set Price Target	Buy	$16.00	N/A
7/28/2016	Brean Capital	Set Price Target	Buy	$20.00	N/A
7/28/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$16.00	N/A

(Data available from 6/18/2016 forward)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $19.17

$19.17

$19.76

50 Day Range

MA: $17.73

$15.92

$19.55

52 Week Range

Now: $19.17

$9.00

$20.51

Volume

837,713 shs

Average Volume

482,723 shs

Market Capitalization

$1.07 billion

P/E Ratio

33.63

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Vanda Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Vanda Pharmaceuticals in the last year: Bank of America Co., Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., Smith Barney Citigroup, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for VNDA.

What is the current price target for Vanda Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Vanda Pharmaceuticals in the last year. Their average twelve-month price target is $17.20, suggesting a possible downside of 10.3%. Bank of America Co. has the highest price target set, predicting VNDA will reach $22.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $14.00 for Vanda Pharmaceuticals in the next year.
View the latest price targets for VNDA.

What is the current consensus analyst rating for Vanda Pharmaceuticals?

Vanda Pharmaceuticals currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VNDA will outperform the market and that investors should add to their positions of Vanda Pharmaceuticals.
View the latest ratings for VNDA.

What other companies compete with Vanda Pharmaceuticals?

Other companies that are similar to Vanda Pharmaceuticals include Amgen, Gilead Sciences, Biogen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Vanda Pharmaceuticals' investor relations team?

Vanda Pharmaceuticals' physical mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company's listed phone number is 202-734-3400 and its investor relations email address is [email protected] The official website for Vanda Pharmaceuticals is www.vandapharma.com.